⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DRUG News
Bright Minds Biosciences Inc. Common Stock
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference
globenewswire.com
DRUG
FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order
globenewswire.com
DRUG
Drug Farm Announces U.S. FDA Orphan Drug Designation for DF-003 for the Treatment of ROSAH Syndrome
businesswire.com
DRUG
Bright Minds Biosciences to Present at Upcoming Conferences
globenewswire.com
DRUG
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
globenewswire.com
DRUG
Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock
globenewswire.com
DRUG
Bright Minds Biosciences Announces Launch of US$100 Million Public Offering
globenewswire.com
DRUG
Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)
globenewswire.com
DRUG
Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026
globenewswire.com
DRUG
Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting
globenewswire.com
DRUG